Masashi Shimazaki

Astellas Pharma (Japan) — Japan

Medicine · Health Sciences

14h-index1.1kcitations25works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(6), Cardiac Fibrosis and Remodeling(6), Protein Kinase Regulation and GTPase Signaling(5), Signaling Pathways in Disease(5), Cancer therapeutics and mechanisms(4)

Publications25 total

Study of Magnetization Method for Passively Controlled Zero Power Magnetic Bearings of Bearingless Motors for VAD Pumps
2025
Discovery of ASP2453, a potent and orally bioavailable covalent inhibitor of KRAS G12C for the treatment of solid tumors
Results in Chemistry·2025Open Access
1323 A novel bispecific antibody targeting CD137 and CLDN4 for treating patients with solid tumors
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure–activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors
Bioorganic & Medicinal Chemistry·2023· 5 cited
Abstract A173: ASP2074, a novel tetraspanin 8 x CD3 bispecific antibody, demonstrates selectivity and antitumor activity in preclinical cancer models
Molecular Cancer Therapeutics·2023
Abstract LB246: Enfortumab vedotin, a nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models which predicts minimal systemic exposure when administered by intravesical instillation in patients
Cancer Research·2023
Abstract 2962: ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models
Cancer Research·2023· 8 cited
1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors
Regular and Young Investigator Award Abstracts·2022· 14 citedOpen Access
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity
Bioorganic & Medicinal Chemistry·2022· 14 citedOpen Access
Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer
Cancer Research·2022· 3 cited
Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
British Journal of Cancer·2021· 23 citedOpen Access
Virtual clinical trial simulations for a novel KRAS<sup>G12C</sup> inhibitor (ASP2453) in non‐small cell lung cancer
CPT Pharmacometrics & Systems Pharmacology·2021· 15 citedOpen Access
Movement Track of Cathode Spot Affected by Applying Alternating Magnetic Field
Bulletin of the American Physical Society·2018
Clinical activity of <scp>ASP</scp>8273 in Asian patients with non‐small‐cell lung cancer with <scp>EGFR</scp> activating and T790M mutations
Cancer Science·2018· 15 citedOpen Access
OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
Journal of Thoracic Oncology·2017· 1 citedOpen Access
Post-marketing Surveillance (PMS) of all Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13 935 Patients
Japanese Journal of Clinical Oncology·2011· 15 citedOpen Access
Delayed Re-Epithelialization in Periostin-Deficient Mice during Cutaneous Wound Healing
PLoS ONE·2011· 142 citedOpen Access
Periostin Associates with Notch1 Precursor to Maintain Notch1 Expression under a Stress Condition in Mouse Cells
PLoS ONE·2010· 64 citedOpen Access
[Periostin, acting in regeneration of periodontal ligament, contributes to cardiac healing and tumor capsule formation].
PubMed·2009· 4 cited
Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos–overexpressing bone lesions
Human Pathology·2008· 95 cited
page 1 of 2Next →

Frequent Co-authors

Akira Kudō(9), Isao Kii(7), Takashi Nishiyama(6), Masashi Fukayama(6), Takeshi Kashima(5), Takeyuki Nagashima(5), Kazuyuki Kuramoto(4), Kenichi Mori(4), Norio Amizuka(3), Minqi Li(3), Ayako Nakayama(3), Yoshihiro Nishizono(3), Devra J. Olson(3), Kelly Hensley(3), Christopher Carosino(3), Sharsti Sandall(3), Tomoyoshi Imaizumi(3), Takahiro Nigawara(3), Takanori Koike(3), Yoshiki Satake(3)